Motif Bio (MTFB)
(Delayed Data from NSDQ)
$0.11 USD
-0.01 (-4.63%)
Updated Dec 16, 2019 03:59 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Motif Bio Plc [MTFB]
Reports for Purchase
Showing records 1 - 20 ( 42 total )
Company: Motif Bio Plc
Industry: Medical - Biomedical and Genetics
Company: Motif Bio Plc
Industry: Medical - Biomedical and Genetics
We are terminating coverage of Motif Bio Plc due to reallocation of resources within our coverage universe.
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Motif Bio Plc
Industry: Medical - Biomedical and Genetics
Company: Motif Bio Plc
Industry: Medical - Biomedical and Genetics
FDA Audience Granted; Outcome Remains Uncertain; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Motif Bio Plc
Industry: Medical - Biomedical and Genetics
Complete Response Letter Casts Heavy Cloud; Downgrading to Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Motif Bio Plc
Industry: Medical - Biomedical and Genetics
Company: Motif Bio Plc
Industry: Medical - Biomedical and Genetics
Company: Motif Bio Plc
Industry: Medical - Biomedical and Genetics
Company: Motif Bio Plc
Industry: Medical - Biomedical and Genetics
Additional Pooled Analysis Iclaprim Data Presented at IDWeek; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Motif Bio Plc
Industry: Medical - Biomedical and Genetics
Company: Motif Bio Plc
Industry: Medical - Biomedical and Genetics
1H18 Financial Results Reported; Iclaprim Launch Perspectives; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Motif Bio Plc
Industry: Unclassified
Company: Motif Bio Plc
Industry: Unclassified
Iclaprim Filing Accepted; Priority Review Accorded; Potential Approval in Early 2019; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Motif Bio Plc
Industry: Unclassified
Two Method-of-Use Patents Allowed; Potential Protection to 2037; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Motif Bio Plc
Industry: Unclassified
Iclaprim New Drug Application Submitted; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Motif Bio Plc
Industry: Unclassified
Company: Motif Bio Plc
Industry: Unclassified
Company: Motif Bio Plc
Industry: Unclassified
Pooled Analyses of Pivotal Trial Data Underscore Value Proposition; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Motif Bio Plc
Industry: Unclassified
Company: Motif Bio Plc
Industry: Unclassified
Iclaprim New Drug Application Filing Completion Approaches; ECCMID Presentations; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R